COVID-19 Vaccination During Pregnancy Significantly Reduces Preeclampsia Risk

A large international study has revealed that COVID-19 vaccination during pregnancy, particularly with a booster dose, substantially lowers the risk of preeclampsia, a serious and potentially life-threatening pregnancy complication. The findings, published in eClinicalMedicine, offer new insights into preeclampsia prevention, independent of the direct effects of COVID-19 infection.

Preeclampsia and COVID-19: A Dangerous Overlap

Preeclampsia is a leading cause of both maternal and neonatal morbidity, and mortality. It shares key risk factors with COVID-19, including inflammation and vascular dysfunction . This overlap highlights the importance of preventative measures, especially during and after the pandemic.

Study Details: A Global Perspective

The study, conducted by the INTERCOVID Consortium, analyzed data from 6,527 pregnant women across 18 countries between 2020 and 2022 . Researchers compared vaccination status, SARS-CoV-2 infection rates, and preeclampsia incidence to determine the impact of vaccination.

Key Findings: Vaccination Offers Significant Protection

• COVID-19 Infection Risk: COVID-19 infection during pregnancy was associated with a 45% increased risk of preeclampsia, rising to 78% among unvaccinated women .
• Booster Dose Benefits: Vaccination, particularly with a booster dose, reduced the overall odds of preeclampsia by 33% .
• Protection for Women with Pre-existing Conditions: For women with pre-existing health conditions like diabetes, hypertension, or thyroid disorders, vaccination with a booster cut preeclampsia risk by 42% .
• Improved Outcomes Beyond Preeclampsia: Vaccinated women likewise experienced lower rates of preterm delivery, maternal and perinatal morbidity, and mortality . Specifically, a booster dose was linked to a 33% lower chance of preterm birth, a 32% reduction in maternal morbidity and mortality, and a 29% decrease in perinatal morbidity.

Understanding Potential Biases

Researchers acknowledge potential limitations, including the risk of selection bias related to vaccination uptake and the possibility of residual confounding variables. They caution against overstating results without considering statistical significance .

Looking Ahead: The Importance of Continued Research

These findings underscore the importance of strengthening COVID-19 vaccination programs during pregnancy, ensuring equitable access to vaccines, and prioritizing booster doses. Further research is needed to better understand the underlying mechanisms of preeclampsia and how the immune system interacts with infections and vaccination .